PPARG | PPAR gamma (p-S112) Rabbit pAb (一抗) - WB,IHC-P,IHC-F,IF,Flow-Cyt,ICC/IF,ELISA | Bioss

bs-3737R

磷酸化抗体、宠物抗体、农牧业/家禽抗体

PPARG | PPAR gamma (p-S112) Rabbit pAb

磷酸化过氧化酶活化增生受体γ抗体

CIMT1; FPLD3; GLM1; NR1C3; PPARG1; PPARG2; PPARG5; PPARgamma; PPAR-gamma; PPAR-gamma2; PPARgamma2; PPARG_HUMAN; PPARG; Nuclear receptor subfamily 1 group C member 3; PPARG_MOUSE; PPARG_RAT; peroxisome proliferator activated receptor gamma; peroxisome proliferative activated receptor, gamma; peroxisome proliferator-activated receptor gamma; PPARG | PPAR gamma (phospho-S112); p-PPAR gamma; phospho-PPAR gamma; p-PPARG; PPARG | PPAR gamma (phospho-Ser112)

Rabbit

KLH conjugated synthesised phosphopeptide derived from human PPAR Gamma around the phosphorylation site of ser112: PA(p-S)PP

IgG

Liquid

affinity purified by Protein A

Polyclonal

57 kDa

52 kDa

1mg/ml

0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

类固醇受体（Steroid Receptors）
过氧化物酶体增殖物激活受体γ（PPARγ）主要存在于白色脂肪组织，PPARγ对于脂肪生成、血糖稳定、炎症反应、动脉粥样硬化和肿瘤等的发生都起到重要的作用。主要在脂肪细胞内表达。PPARγ是噻唑烷二酮类药物（TZDs）作用的药靶，又是脂肪细胞分化的重要调节因子。经研究发现，PPARγ在肥胖及胰岛素抵抗的发病机制中具有十分重要的意义，是治疗糖尿病、肥胖等代谢性疾病的重要药靶。
过氧化物酶体增殖物激活受体γ（PPARγ）属Ⅱ型核受体超家族成员，主要在脂肪细胞内表达。PPARγ是噻唑烷二酮类药物（TZDs）作用的药靶，又是脂肪细胞分化的重要调节因子。现有研究（包括一次于美国加州大学进行的研究）发现PPARγ在肥胖及胰岛素抵抗的发病机制中具有十分重要的意义，是治疗糖尿病、肥胖等代谢性疾病的重要药靶。目前，该受体蛋白质水平的筛选模式已经建立，并正在建立该受体的报告基因的细胞水平筛选评价模式。

This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms have been described. [provided by RefSeq, Jul 2008]

PPARG

Peroxisome proliferator-activated receptor gamma

Heterodimer; with RXRA. This heterodimerization is required for DNA binding and transactivation activity. Interacts with AKAP13, LPIN1 and PRDM16. Also interacts with PPARBP coactivator in vitro. Interacts with CITED2; the interaction stimulates its transcriptional activity (By similarity). Interacts with NCOA3 and NCOA6 coactivators. Interacts with ASXL1 AND ASXL2.

Nuclear

Skeletal muscle, liver, heart and kidney.

Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer.
Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.
Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.
Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.

Belongs to the nuclear hormone receptor family. NR1 subfamily. Contains 1 nuclear receptor DNA-binding domain.

Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety (By similarity). Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2.